Beta‐amyloid is the most promising target for Alzheimer’s disease treatment

Our pioneering data were recently confirmed by successful Aducanumab (3-7) and Lecanemab (1-16) antibodies that recognize the N terminus of Aβ and selectivity bind to aggregated Aβ species. Naturally occurring anti-AβP antibodies have been found in human CSF and in the plasma of healthy individuals, from where Aducanumab was derived, but were significantly lower in Alzheimer's disease patients.